Skip to main content

Table 3 CEC, V-CEC, and CEP levels among different clinical conditions

From: Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy

 

CEC

V-CEC

CEP

Variable

Coef* (cells/μL)

p value

Coef (cells/μL)

p value

Coef (cells/μL)

p value

Tumor bearing

−0.57

0.74

−1.08

0.46

0.10

0.44

Chemotherapy regimen*

CEF

0.04

0.99

0.65

0.82

0.12

0.64

Liposomal doxorubicin

−3.00

0.58

−0.43

0.92

−0.03

0.93

N-HDFL

1.79

0.70

3.22

0.40

0.20

0.55

TCH

−1.42

0.63

−0.55

0.82

0.01

0.98

TEC

1.08

0.79

2.50

0.45

0.27

0.32

TH

(Ref)

 

(Ref)

 

(Ref)

 

G-CSF use

0.03

0.85

−0.02

0.86

−0.004

0.78

  1. *Coef = adjusted regression coefficient.
  2. *CEF: cyclophosphamide, epirubicin, fluorouracil.
  3. N-HDFL: vinorelbine, continuous infusion fluorouracil and leucovorin.
  4. TCH: docetaxel, carboplatin, herceptin.
  5. TEC: docetaxel, epirubicin, cyclophosphamide.
  6. TH: docetaxel, herceptin.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us